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retrieved from the medical records of a group of GERD
patients in Hong Kong. Sensitivity analysis was 
conducted to examine the robustness of the model.
RESULTS: The cost-effectiveness ratios (CERs) of 
standard-dose H2RA, low-dose PPI and standard-dose
PPI per asymptomatic patient-month were HKD644, 660
and 873, respectively (1USD = 7.8HKD). The incremen-
tal CER (ICER) of low-dose PPI comparing to standard-
dose H2RA was HKD1,241 per additional asymptomatic
patient-month gained, while the ICER of standard-dose
PPI comparing to low-dose PPI was HKD11,766 per
additional asymptomatic patient-month gained. One-way
sensitivity analysis showed that the CER of standard-dose
PPI was insensitive to variation of all the inputs of the
model. The CERs of low-dose PPI and standard-dose
H2RA were sensitive to the variation of relapse rate of
H2RA and direct medical cost per symptomatic patient-
month. CONCLUSION: Based on the Markov analysis
of the data obtained, standard-dose PPI was more expen-
sive but more effective than low-dose PPI or standard-
dose H2RA for maintenance treatment of patients with
GERD.
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OBJECTIVE: To compare the cost-effectiveness of
esomeprazole 40mg od or omeprazole 20mg od in the
acute treatment of patients with reﬂux oesophagitis 
in Greece. METHODS: A simple decision analysis 
model was designed to compare the cost-effectiveness of
esomeprazole vs. omeprazole during eight weeks’ acute
treatment of reﬂux oesophagitis patients. Omeprazole,
the leading PPI in Greece, was chosen as the comparator.
Probability of treatment success was based on pooled
healing rates (Life Table estimates) from 3 clinical studies
(N = 4877). Only direct medical costs were included in
the cost-effectiveness analysis. As patients can unrestrict-
edly visit public or private sector GPs or gastroenterolo-
gists, all patients were assumed to visit a specialist. 
An endoscopy was assumed to be carried out in non-
responders after eight weeks’ of therapy, which is a con-
servative patient management assumption, according to
results obtained from a market research among Greek
gastroenterologists. Furthermore, the analysis did not
consider additional treatment costs (e.g. drugs, visits) for
failures beyond eight weeks. One analysis was carried 
out by using private market and one by using public hos-
pital endoscopy and visit charges. RESULTS: Healing
rates from the pooled analysis showed that esomeprazole
is signiﬁcantly more effective than omeprazole. After 4
weeks of therapy, healing rates were 77.7% for esomepra-
zole compared with 67.6% for omeprazole (p < 0.001).
The corresponding values after 8 weeks treatment were
93.4% and 86.2%, respectively (p < 0.001). The decision
analysis model resulted in similar direct medical costs for
the esomeprazole and the omeprazole strategy, both when
using public (€328 vs. €330) and private charges (€353
vs. €356). CONCLUSIONS: Despite using conservative
assumptions, esomeprazole 40mg od was found to be
cost-effective compared with omeprazole 20mg od in the
acute treatment of patients with reﬂux oesophagitis in
Greece, since esomeprazole provides better effectiveness
at no additional treatment costs.
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The recommended Helicobacter Pylori (H. Pylori) eradi-
cation treatment strategy in duodenal ulcer (DU) disease
includes one-week proton pump inhibitor (PPI) triple
therapy regimens followed by PPI monotherapy for three
weeks. Triple therapy regimens of omeprazole, amoxi-
cillin and clarithromycin (OAC) are the most widely used
regimens in Greece. Esomeprazole, the ﬁrst PPI developed
as an optical isomer, has been shown to achieve greater
and more sustained acid control than omeprazole, with 
a similar tolerability and safety proﬁle. Results from 
two clinical studies reveal that eradication regimens 
with esomeprazole 1-week triple therapy (esomeprazole,
amoxicillin, clarithromycin) (EAC) without subsequent
three weeks monotherapy show comparable eradication
rates with OAC including 3 weeks monotherapy (EAC:
90%, n = 204, OAC: 88%, n = 196; EAC: 86%, n = 214,
OAC: 88%, n = 219). OBJECTIVE: To evaluate the
potential cost savings associated with eradication of H.
Pylori with EAC 1-week therapy compared with OAC 1-
week therapy followed by 3 weeks omeprazole monother-
apy in patients with DU in Greece. METHODS: Patient
management in clinical practice was investigated through
market research of 10 Greek gastroenterologists. A 
cost analysis was performed to assess incremental direct
medical costs associated with the esomeprazole and
omeprazole based eradication strategies. The perspective
of the analysis was that of the Greek health care system
(Greek public sector charges). RESULTS: The cost analy-
sis showed that eradication treatment with esomeprazole
therapy results in a cost per patient of €114,57 while
treatment with omeprazole results in a corresponding cost
per patient of €158,18. Thus, esomeprazole therapy 
provides cost savings of 28% (€43,6) per patient when
compared with omeprazole therapy. CONCLUSION:
Eradication of H. Pylori with 1-week triple therapy with
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esomeprazole (EAC) results in direct medical cost savings
compared with 1-week triple therapy (OAC) followed 
by three weeks omeprazole monotherapy, while offering
comparable effectiveness.
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OBJECTIVES: In the assessment of NSAID related GI
events, many authors focus on severe events leading to
hospitalisation. This study aimed at describing medical
practice, resource utilisation and costs of different GI
events related to chronic NSAID use in osteo-arthritis
(OA) and rheumatoid arthritis (RA) patients in Belgium.
METHODS: A random sample of 231 OA and RA
patients with GI events associated with NSAID use was
included in a multicenter GP level chart review. Charts
were assessed by the GP and monitored by an indepen-
dent researcher for all medical resource use related to the
event. Direct medical costs were calculated by multiply-
ing resource use with standard costs for the health insur-
ance. GI events were categorised as GI discomfort (=
minor event), symptomatic ulcer, anaemia with occult
bleeding and severe (i.e. hospitalised) gastro-intestinal
pathologies. RESULTS: Thirty-ﬁve patients (15.2%) were
RA patients, 196 (84.8%) OA. The average age of the
sample was 61.0y (st.dev 14.7y). 45% were male. The
median duration of a GI event was 10 days, the average
was 23 days. The average cost per patient was €284. The
cost per type of event (in €) was as follows (p < 0.001
Kruskal Wallis): GI Discomfort (n = 155): 198 (SE = 41);
Ulcer (n = 66): 364 (SE = 28); Anaemia (n = 7): 756 (SE
= 234); Severe GI (n = 3): 1,896 (SE = 1,585). Total cost
(n x mean) was: GI Discomfort: 30,657 (46.7%); Ulcer:
24,020 (36.6%); Anaemia: 5,293 (8.1%); Severe GI:
5,688 (8.7%). It was thus shown that GI discomfort, due
to the relative high number of patients, leads to 47% of
total GI related costs. CONCLUSIONS: Many patients
with minor NSAID related GI events visit a physician.
The resulting use of healthcare resources to manage these
events should be taken into account in economic evalua-
tions of measures to prevent GI events.
GASTROINTESTINAL DISEASES/DISORDERS—
Clinical Outcomes
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OBJECTIVE: Two studies have reported results compar-
ing esomeprazole 40mg and lansoprazole 30mg in the
healing of reﬂux oesophagitis. The two studies come to
different conclusions. One study shows superiority for
esomeprazole at four and eight weeks while the other
claims equivalence. The aim of this work was to combine
the results of the 2 studies by meta-analysis to ascertain
if there is a difference in healing rates with esomeprazole
40mg and lansoprazole 30mg. METHODS: Meta-
analysis of intention-to-treat (ITT) endoscopic healing
rates at four and eight weeks. If the healing rates were
not presented in an ITT format they were recalculated.
ITT was deﬁned as “patients being analysed in the treat-
ment arm that they entered at randomisation, regardless
of whether they dropped-out, received the incorrect
treatment or withdrew before completion of the trial”.
RESULTS: At 4 weeks, esomeprazole 40mg is signiﬁ-
cantly more effective than lansoprazole 30mg in the
healing of reﬂux oesophagitis (Relative Risk 1.05; 95%
CI 1.02–1.09). Similarly, at 8 weeks esomeprazole 40mg
is signiﬁcantly more effective than lansoprazole 30mg
(Relative Risk 1.04; 95% CI 1.01–1.06). A chi-squared
test was carried out to investigate possible heterogeneity.
Signiﬁcant heterogeneity was not detected at four or eight
weeks. CONCLUSIONS: Esomeprazole 40mg is signiﬁ-
cantly more effective than lansoprazole 30mg in the
healing of reﬂux oesophagitis at 4 and 8 weeks.
PGS9
OUTCOMES ANALYSIS OF RABEPRAZOLE
(ACIPHEX) USE AT A VETERAN AFFAIRS
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OBJECTIVE: To analyze the safety, effectiveness and cost
savings of rabeprazole at the McGuire Veterans Affairs
Medical Center. Similar effectiveness and safety pro-
ﬁles among the proton pump inhibitors (PPI) prompted 
a dose-per-dose interchange (1 :1) of rabeprazole with 
currently prescribed PPIs (lansoprazole and omeprazole)
when rabeprazole was added to the VA National Formu-
lary priced 75%–80% less than its competitors. Rabepra-
zole was also identiﬁed as drug-of-choice for future use
in PPI-naïve patients. METHODS: Patients with active
rabeprazole prescriptions (N = 3885) and those failing
therapy (N = 249) as of 5/22/02 were selected for analy-
sis (total N = 4134). Patients were divided into two
subsets: those participating in the PPI therapeutic inter-
change: N = 2088; and PPI-naïve patients prescribed
rabeprazole after formulary addition: N = 1797. A retro-
spective database analysis of 14,565 PPI prescriptions
from January 1, 2000–May 22, 2002 was conducted to
assess PPI prescribing trends, pharmacy acquisition costs,
tolerance, effectiveness and dose creep for these individ-
uals. RESULTS: Safety: Patients experience an adverse
drug event (ADE): N = 65 (1.6%). Effectiveness: Patients
failing rabeprazole: N = 184 (4.5%). Total number 
